Alnylam Pharmaceuticals Canada

Gold Sponsor

Focus: Neurology – Hereditary TTR Amyloidosis, Acute Hepatic Porphyria

Alnylam, founded in 2002, is delivering on a bold vision to turn scientific possibility into reality with a deep pipeline of investigational medicines to address the needs of patients who have limited or inadequate treatment options. Alnylam employs over 1200 people worldwide with Canadian headquarters in Mississauga established in 2018.